0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach

Louise-Laure Mariani, MD1,2; Christelle Tesson, PhD3,4,5; Perrine Charles, MD, PhD1,2; Cécile Cazeneuve, MD1; Valérie Hahn, MS2,6; Katia Youssov, MD7,8,9; Leorah Freeman, MD, PhD2,10; David Grabli, MD, PhD2,3; Emmanuel Roze, MD, PhD2,3,4; Sandrine Noël, BSc1; Jean-Noel Peuvion, BSc1; Anne-Catherine Bachoud-Levi, MD, PhD7,8,9; Alexis Brice, MD1,3,4; Giovanni Stevanin, PhD1,3,4,5; Alexandra Durr, MD, PhD1,3,4
[+] Author Affiliations
1Assistance Publique–Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Genetics, Paris, France
2Assistance Publique–Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Neurology, Paris, France
3Institut du Cerveau et de la Moelle Epinière, Paris, France
4Institut National de la Santé et de la Récherche Médicale Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Sorbonne Universités, Université Pierre et Marie Curie University Paris 06 Unité Mixte de Recherche S1127, Paris, France
5Ecole Pratique des Hautes Etudes, Paris, France
6Assistance Publique–Hôpitaux de Paris, Unité de Neurologie de la Mémoire et du Langage, Centre Hospitalier Saint-Anne, Paris, France
7Assistance Publique–Hôpitaux de Paris, Reference Centre for Huntington’s Disease, Unité Fonctionnelle de Neurologie Cognitive, Henri Mondor University Hospital, Créteil, France
8Institut National de la Santé et de la Récherche Médicale Unité 955 Team 1, Institut Mondor de Recherche Biomédicale, Faculté de Médecine de Créteil, Créteil, France
9Institut d’Etude de la Cognition, Ecole Normale Supérieure, Paris, France
10Department of Neurology, McGovern Medical School, UTHealth, Houston, Texas
JAMA Neurol. 2016;73(9):1105-1114. doi:10.1001/jamaneurol.2016.2215.
Text Size: A A A
Published online

Importance  Huntington disease (HD), a prototypic monogenic disease, is caused by an expanded CAG repeat in the HTT gene exceeding 35 units. However, not all patients with an HD phenotype carry the pathological expansion in HTT, and the positive diagnosis rate is poor.

Objectives  To examine patients with HD phenotypes to determine the frequency of HD phenocopies with typical features of HD but without pathological CAG repeat expansions in HTT in an attempt to improve the positive diagnosis rate.

Design, Setting, and Participants  Between January 1, 2004, and April 18, 2011, a total of 226 consecutive index patients with an HD phenotype were referred to specialized clinics of the French National Huntington Disease Reference Centre for Rare Diseases. They underwent detailed clinical examination and follow-up, as well as neuropsychological, biological, imaging, and genetic examinations. Nucleotide expansions in JPH3, ATN1, TBP, and C9ORF72 and mutations in PRNP, as well as acquired conditions commonly causing HD phenocopies, were first screened.

Main Outcomes and Measures  The diagnostic rate of HD phenocopies and frequency of other etiologies using deep clinical phenotyping and next generation sequencing. Our goal was to improve the genetic diagnosis of HD phenocopies and to identify new HD related genes.

Results  One hundred ninety-eight patients carried a pathological CAG repeat expansion in HTT, whereas 28 patients (12 women and 16 men) did not. Huntington disease phenocopies accounted for 12.4%, and their mean (SD) age at onset was similar to those of the HD-HTT group (47.3 [12.7] years vs 50.3 [16.4] years, P = .29). We first identified 3 patients with abnormal CTG expansions in JPH3, a fourth patient with an antiphospholipid syndrome, and a fifth patient with B12 avitaminosis. A custom-made 63-gene panel was generated based on clinical evolution and exome sequencing. It contained genes responsible for HD phenocopies and other neurodegenerative conditions, as well as candidate genes from exome sequencing in 3 index cases with imaging features of brain iron accumulation. We identified mutations in genes associated with neurodegeneration, including CACNA1A (n = 2), VPS13A (n = 1), UBQLN2 (n = 1), and VCP (n = 1).

Conclusions and Relevance  Huntington disease phenocopies without CAG repeat expansions in HTT are not rare, occurring in 12.4% (28 of 226) herein, and should be considered in genetic counseling. We used next-generation sequencing combined with clinical data and disease evolution to explore multiple etiologies simultaneously. Our combined clinical and genetic exploration of 28 HD phenocopies identified the underlying cause in 35.7% (10 of 28). In conclusion, the etiologies of HD phenocopies are heterogeneous, and clinical evolution should be taken into account when searching for a genetic cause. The panel of candidate genes to be examined is larger than expected but can be guided by specific imaging and clinical features. Other neurodegenerative diseases with late onset in which variant segregation cannot be verified could be productively explored with the combined approach illustrated herein.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Figures

Place holder to copy figure label and caption
Figure.
Flowchart of Patients With Huntington Disease (HD) Phenotype

ALS indicates amyotrophic lateral sclerosis; CT, computed tomography; and MRI, magnetic resonance imaging.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Video.

Patient SAL-315-001 With Neurodegeneration With Brain Iron Accumulation

Some tools below are only available to our subscribers or users with an online account.

461 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();